Serotonin-norepinephrine reuptake inhibitors (SNRIs) block both the serotonin transporter (SERT) and the norepinephrine transporter (NET), producing dual monoaminergic enhancement that distinguishes them mechanistically from SSRIs. The clinical consequences of this dual action extend beyond mood and anxiety to encompass pain modulation, which accounts for the established efficacy of several SNRIs in neuropathic pain and fibromyalgia.
The molecular targets of SNRIs are SERT and NET, both members of the SLC6 solute carrier family of sodium-dependent monoamine transporters. SERT inhibition increases synaptic serotonin (5-hydroxytryptamine, 5-HT) availability in limbic and prefrontal circuits relevant to mood regulation. NET inhibition increases synaptic norepinephrine (NE) in these same circuits and additionally in descending pain modulation pathways in the dorsal horn of the spinal cord, which partly explains why dual reuptake inhibition produces antinociceptive effects that SERT inhibition alone does not reliably achieve.1 The analgesic mechanism involves augmentation of descending noradrenergic and serotonergic inhibitory control over spinal nociceptive transmission, a mechanism shared with tricyclic antidepressants (TCAs) and exploited therapeutically in neuropathic pain and fibromyalgia.
The clinically most consequential pharmacodynamic distinction within the SNRI class is the dose-dependent nature of NET inhibition by venlafaxine. At doses in the range of 75 mg per day or below, venlafaxine behaves predominantly as a SERT inhibitor with a pharmacological profile that resembles an SSRI more than an SNRI. Meaningful NET inhibition begins to emerge at doses of approximately 150 mg per day and becomes increasingly robust at 225 mg per day and above.2 This dose-dependent receptor engagement has practical implications: a patient who fails to respond to venlafaxine at 75 mg has not had an adequate trial of dual reuptake inhibition, and dose escalation to the full therapeutic range is pharmacologically rational before concluding treatment failure. Duloxetine and levomilnacipran, by contrast, achieve clinically significant NET inhibition across their full therapeutic dose ranges and do not exhibit the same degree of dose-dependent duality.
The addition of NE reuptake inhibition to SERT blockade produces a distinct adverse effect profile compared to SSRIs. Noradrenergic activation accounts for the blood pressure elevation, heart rate increase, and increased sweating seen with SNRIs at higher doses; NE also mediates the urinary hesitancy that is more common with SNRIs than with SSRIs. At the same time, noradrenergic activity contributes to the class's established efficacy in stress urinary incontinence (duloxetine is approved for this indication in Europe), and the NET component is thought to contribute to the energizing and pro-cognitive effects that some patients report with SNRIs that are less prominent with pure SERT inhibitors.
Both classes produce antidepressant and anxiolytic effects via serotonergic mechanisms, but SNRIs add noradrenergic augmentation of descending pain inhibitory pathways, giving them established efficacy in neuropathic pain and fibromyalgia that SSRIs lack. The noradrenergic component also increases blood pressure, heart rate, and sweating at higher doses, requiring cardiovascular monitoring not routinely needed with SSRIs.
The four available SNRIs share dual SERT and NET inhibition as their primary mechanism but differ in their pharmacokinetic properties, degree of NET selectivity relative to SERT, approved indications, and clinical niches. Understanding these differences is necessary for rational agent selection.
Venlafaxine is metabolized by cytochrome P450 2D6 (CYP2D6) to its principal active metabolite, O-desmethylvenlafaxine, which has been developed and approved as a separate agent under the name desvenlafaxine. The parent compound has a half-life of approximately five hours for the immediate-release formulation, which necessitates twice-daily dosing and creates a high risk of discontinuation syndrome with missed doses or abrupt cessation. The extended-release formulation (venlafaxine XR) prolongs the half-life to approximately eleven hours and permits once-daily administration. Desvenlafaxine has a half-life of approximately eleven hours and is approved at a fixed dose of 50 mg per day, avoiding the dose titration required for venlafaxine.3 Both agents are renally cleared to a significant degree, with desvenlafaxine excreted approximately 45% unchanged in urine, requiring dose reduction when creatinine clearance falls below 30 mL per minute.
The primary metabolic distinction between venlafaxine and desvenlafaxine is relevant for patients who are CYP2D6 poor metabolizers (PMs). In CYP2D6 PMs, venlafaxine conversion to desvenlafaxine is reduced, producing higher venlafaxine parent concentrations and lower desvenlafaxine levels relative to extensive metabolizers. Since desvenlafaxine has a higher NET-to-SERT inhibition ratio than the parent compound, CYP2D6 PMs on venlafaxine may experience a pharmacological profile that is more SERT-dominant than intended. Desvenlafaxine, not requiring CYP2D6 for its own primary activity, avoids this genotypic variability. Both venlafaxine and desvenlafaxine are weak inhibitors of CYP2D6 and have minimal clinically significant CYP interactions at standard doses. Pooled analyses of venlafaxine clinical trials suggested higher remission rates compared to SSRIs, an effect attributed to its dual mechanism at higher doses.5
Duloxetine is metabolized primarily by CYP1A2 and CYP2D6, has a half-life of approximately twelve hours, and is dosed once or twice daily. It achieves meaningful inhibition of both SERT and NET across its full therapeutic dose range of 60 to 120 mg per day, without the dose-dependent duality seen with venlafaxine.13 Duloxetine has the broadest approval portfolio of the SNRI class: it is FDA-approved for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain. Its established analgesic efficacy across multiple pain conditions has made it a first-line agent in several chronic pain guidelines. Duloxetine is a moderate inhibitor of CYP2D6 and can raise plasma concentrations of CYP2D6 substrates, including TCAs and certain antipsychotics, by approximately two- to threefold; this interaction requires monitoring when duloxetine is added to regimens containing CYP2D6-dependent drugs. Protein binding is approximately 96%. Duloxetine is contraindicated in patients with uncontrolled narrow-angle glaucoma due to mydriatic effects. Hepatotoxicity, while rare, has been reported; duloxetine should be avoided in patients with substantial alcohol use or pre-existing hepatic disease.
Levomilnacipran is the active 1S,2R enantiomer of milnacipran, a compound used clinically in Europe and Japan for depression and in the United States for fibromyalgia (as racemic milnacipran). Levomilnacipran has a higher NET-to-SERT inhibition ratio than any other approved SNRI, approximately ten to one, giving it a more noradrenergically weighted pharmacological profile than duloxetine or venlafaxine.4 This stronger NET inhibition may translate to more pronounced effects on energy, concentration, and motivation in patients whose depression is characterized by psychomotor slowing, though head-to-head comparative efficacy data against other SNRIs are limited. Levomilnacipran has a half-life of approximately twelve hours, is dosed once daily in the range of 40 to 120 mg per day, and undergoes minimal CYP metabolism, with approximately 58% excreted unchanged in urine. Renal clearance dependence requires dose reduction in renal impairment. CYP drug interaction potential is low, making it one of the cleaner choices for patients on complex regimens.
Duloxetine: MDD, GAD, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain. Venlafaxine XR: MDD, GAD, social anxiety disorder (SAD), panic disorder. Desvenlafaxine: MDD only. Levomilnacipran: MDD only. For patients in whom analgesic effect is a co-primary treatment goal, duloxetine or venlafaxine are the agents with the strongest evidence base.
The cardiovascular effects of SNRIs are a direct pharmacological consequence of NET inhibition. By blocking NE reuptake from sympathetic nerve terminals and central adrenergic synapses, SNRIs increase synaptic NE availability in circuits that regulate blood pressure and heart rate. The resulting sympathomimetic effects are dose-dependent and more prominent at the higher end of each agent's therapeutic range.
Blood pressure elevation is the most clinically significant cardiovascular effect. In clinical trials of venlafaxine, dose-dependent increases in diastolic blood pressure were observed, with mean diastolic increases of approximately 1 to 2 mmHg at doses up to 100 mg per day and 4 to 7 mmHg at doses above 300 mg per day.2 Duloxetine and levomilnacipran also produce mean blood pressure increases that are modest in population averages but can be clinically meaningful in individual patients, particularly those with pre-existing hypertension or cardiovascular disease. Clinically significant hypertension, defined as a sustained diastolic blood pressure above 90 mmHg in a previously normotensive patient, occurs in approximately 3% to 5% of patients on therapeutic SNRI doses.
The practical monitoring protocol for SNRI initiation involves measuring blood pressure at baseline, at each dose increase, and at regular intervals during maintenance. For patients with pre-existing hypertension who require an SNRI, optimizing antihypertensive therapy before SNRI initiation and monitoring blood pressure more frequently after initiation is the recommended approach. If sustained blood pressure elevation develops on an SNRI, options include dose reduction, addition of an antihypertensive agent, or switching to an SSRI or another antidepressant class with a lower cardiovascular burden. SNRIs should be used with particular caution in patients with poorly controlled hypertension, recent myocardial infarction, or unstable angina, where sympathomimetic activation carries greater risk.
Heart rate effects are generally modest with SNRIs as a class, with mean increases in the range of two to four beats per minute reported across clinical trials. However, individual patients may experience more pronounced tachycardia, particularly at higher doses of levomilnacipran given its stronger NET inhibition. Urinary hesitancy and retention, mediated by NE-driven contraction of the internal urethral sphincter and relaxation of the detrusor muscle via alpha-1 adrenergic stimulation, are more common with SNRIs than with SSRIs and require monitoring in elderly males and patients with bladder outflow obstruction. Sweating, another noradrenergic adverse effect, is frequently reported with SNRIs and can contribute to patient-initiated discontinuation.
SNRIs, particularly venlafaxine immediate-release, carry a high risk of discontinuation syndrome given their short half-lives. The FINISH syndrome (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) can begin within 24 hours of missed doses of short-acting formulations. Venlafaxine XR reduces but does not eliminate this risk. Gradual tapering over weeks to months is required for most patients, with the rate of taper guided by symptom emergence. Converting from venlafaxine immediate-release to the XR formulation or to fluoxetine (which provides a pharmacokinetic bridge via its long half-life) are established clinical strategies for managing difficult venlafaxine discontinuations.
Mirtazapine belongs to the noradrenergic and specific serotonergic antidepressant (NaSSA) class and operates through a mechanism entirely distinct from SSRIs and SNRIs. Rather than blocking monoamine reuptake transporters, mirtazapine acts as an antagonist at multiple receptor targets to disinhibit NE and 5-HT release and simultaneously block specific postsynaptic 5-HT receptor subtypes, producing a net enhancement of serotonergic and noradrenergic neurotransmission through indirect mechanisms.
Mirtazapine's primary mechanism involves blockade of presynaptic alpha-2 adrenergic autoreceptors on noradrenergic cell bodies and terminals. Alpha-2 autoreceptors normally function as a negative feedback brake: NE released into the synapse activates these receptors, suppressing further NE release. By blocking alpha-2 autoreceptors, mirtazapine removes this inhibitory brake, increasing the rate and amount of NE released with each action potential.6 Mirtazapine also blocks alpha-2 heteroreceptors located on serotonergic terminals, where they normally suppress 5-HT release; blockade of these heteroreceptors disinhibits 5-HT release as well. The net effect is enhanced NE and 5-HT output without requiring transporter blockade.
At the postsynaptic level, mirtazapine is a potent antagonist at 5-HT2A, 5-HT2C, and 5-HT3 receptors. Blockade of 5-HT2A receptors is thought to contribute to anxiolytic and antidepressant effects and reduces the sexual dysfunction and agitation that can arise from excess 5-HT2A stimulation with SSRIs. Blockade of 5-HT3 receptors produces a pronounced antiemetic effect and prevents the nausea that frequently limits SSRI tolerability in the first weeks of treatment. Blockade of 5-HT2C receptors increases appetite and promotes weight gain, which can be therapeutically useful in patients with poor appetite and significant weight loss from depression, but is an adverse effect in patients who are already overweight. Mirtazapine also has potent histamine H1 receptor antagonism, which accounts for its marked sedative effect, particularly at lower doses.6
A counterintuitive pharmacodynamic feature of mirtazapine is that its sedative effect is more pronounced at lower doses and diminishes somewhat at higher doses. This occurs because H1 antagonism, which drives sedation, is maximal across the full dose range, while the alpha-2 blockade-mediated increase in NE output at higher doses produces a degree of noradrenergic activation that partially counteracts histaminergic sedation. Clinically, this means that patients who experience problematic daytime sedation at 15 mg may tolerate 30 mg better, rather than the usual expectation that higher doses produce more sedation.
Mirtazapine is well absorbed orally with bioavailability of approximately 50%, undergoes extensive hepatic metabolism by CYP1A2, CYP2D6, and CYP3A4, and has a half-life of twenty to forty hours, allowing once-daily dosing, typically at bedtime to exploit its sedative properties.7 It has no clinically significant CYP inhibition, making it one of the cleaner choices in terms of drug interaction burden. Protein binding is approximately 85%. No active metabolites contribute meaningfully to its clinical effects.
Mirtazapine's clinical niche is defined by its receptor profile. It is particularly well-suited for patients who cannot tolerate SSRI-associated nausea, patients with insomnia as a prominent feature of depression, patients with significant weight loss or poor appetite, and patients in whom sexual dysfunction from serotonergic agents is unacceptable. It lacks the sexual dysfunction associated with SERT-inhibiting antidepressants because it does not increase serotonergic tone via the 5-HT2A pathway responsible for this adverse effect. Its absence of CYP inhibition and its different receptor mechanism also make it a useful augmentation agent alongside SSRIs or SNRIs, a combination that provides complementary mechanisms: reuptake inhibition plus presynaptic disinhibition and postsynaptic 5-HT2 blockade.12
Mirtazapine produces among the most significant weight gain of any antidepressant, driven primarily by 5-HT2C and H1 receptor antagonism, which increase appetite and reduce metabolic rate. Mean weight gain of three to four kilograms over the first several months of treatment is typical, and some patients gain considerably more. This should be discussed explicitly before initiation. For patients in whom weight gain would represent a significant health risk or would undermine treatment adherence, mirtazapine may not be the optimal choice despite its other advantages.
Bupropion is the sole clinically available norepinephrine-dopamine reuptake inhibitor (NDRI) and the only antidepressant with established efficacy as a primary smoking cessation pharmacotherapy. Its complete lack of serotonergic activity produces a sexual side effect and nausea profile that is markedly more favorable than SSRIs or SNRIs, but its dose-dependent lowering of the seizure threshold imposes a hard ceiling on dosing and creates several absolute contraindications.
Bupropion inhibits NET and the dopamine transporter (DAT) with minimal effect on SERT. The relative potency of NET inhibition exceeds DAT inhibition at therapeutic concentrations, making bupropion primarily a noradrenergic agent with a secondary dopaminergic component. Its active metabolites, particularly hydroxybupropion, contribute substantially to its pharmacological activity and have longer half-lives than the parent compound, maintaining therapeutic effect between doses.8 The dopaminergic activity distinguishes bupropion from other antidepressants and accounts for both its utility in smoking cessation and its stimulant-like properties, including insomnia, reduced appetite, and activation, which are reported more frequently with bupropion than with SSRIs or SNRIs.
The mechanism underlying bupropion's antidepressant efficacy is not fully established. NE reuptake inhibition contributes to antidepressant and antianxiety effects analogously to other NE-enhancing antidepressants. The dopaminergic component may specifically address anhedonia and amotivation, which are driven by reduced dopaminergic tone in mesolimbic and mesocortical circuits. Bupropion is therefore sometimes preferred in patients whose depression is characterized predominantly by low energy, anhedonia, hypersomnia, and cognitive slowing, rather than in those with prominent anxiety, where its activating properties can worsen symptoms.
Bupropion lowers the seizure threshold in a dose-dependent manner, and this property is the most clinically consequential safety feature of the drug. The seizure risk at standard doses (up to 300 mg per day of immediate-release or 450 mg per day of extended-release formulations) is estimated at approximately 0.1%, comparable to other antidepressants. Above the maximum recommended doses, seizure risk rises sharply and is no longer acceptable.9 Single doses above 150 mg of the immediate-release formulation carry disproportionately high seizure risk due to rapid peak plasma concentrations, which is why the immediate-release formulation must be dosed two to three times daily with no single dose exceeding 150 mg. The extended-release formulation, by reducing peak concentrations, substantially mitigates but does not eliminate this risk.
Absolute contraindications based on seizure risk include: a history of seizure disorder of any etiology; current or recent use of monoamine oxidase inhibitors (MAOIs), which in combination with bupropion can produce severe neurotoxicity; abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs, as withdrawal lowers the seizure threshold independently; and eating disorders involving purging behavior, specifically bulimia nervosa and anorexia nervosa with purging, where electrolyte abnormalities (particularly hypokalemia and hypomagnesemia) reduce the seizure threshold synergistically with bupropion's pharmacological effect. Head trauma and central nervous system (CNS) tumors also lower the seizure threshold and are relative contraindications requiring individualized risk assessment.
Bupropion was the first non-nicotine pharmacotherapy approved for smoking cessation, initially under the brand name Zyban. Its efficacy in smoking cessation is thought to be mediated primarily through its dopaminergic activity. Nicotine addiction is maintained in part by nicotine-stimulated dopamine release in the nucleus accumbens, producing reinforcement and reward; bupropion's DAT inhibition raises basal dopamine tone and may attenuate the withdrawal-associated drop in dopaminergic activity that drives craving and relapse.10 Bupropion also weakly blocks nicotinic acetylcholine receptors, which may reduce the pleasurable effects of cigarettes if the patient smokes while on treatment. In smoking cessation trials, bupropion approximately doubles quit rates compared to placebo, an effect that is additive when combined with nicotine replacement therapy. The standard smoking cessation protocol initiates bupropion one to two weeks before the target quit date, allowing plasma levels to reach steady state before the patient attempts cessation.
Bupropion is well absorbed orally but undergoes extensive first-pass hepatic metabolism, primarily by CYP2B6, producing three active metabolites: hydroxybupropion (the most pharmacologically active), threohydrobupropion, and erythrohydrobupropion. The parent compound has a half-life of approximately fourteen hours; hydroxybupropion's half-life is approximately twenty hours, contributing to the overall extended pharmacological duration.8 Bupropion is a potent inhibitor of CYP2D6, a clinically important interaction that mirrors paroxetine and fluoxetine in its consequences: co-administration with TCAs, certain antipsychotics, or other CYP2D6 substrates requires monitoring for toxicity from elevated substrate levels. Protein binding is approximately 84%. No dose adjustments are required for mild renal impairment, but caution is warranted in severe hepatic impairment given the hepatic metabolism of both parent and active metabolites.
Bupropion's complete absence of serotonergic activity means it does not produce the sexual dysfunction, specifically impaired desire, delayed orgasm, and erectile dysfunction, that affects approximately 30% to 40% of patients on SSRIs or SNRIs. It is used both as a primary antidepressant in patients for whom sexual function is a priority and as an augmentation agent added to an SSRI or SNRI specifically to counteract serotonergic sexual adverse effects. Evidence from randomized controlled trials supports both uses, with the caveat that adding bupropion to an SSRI further raises the seizure risk above either drug alone.11
Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66(6):355–474.
doi:10.1016/S0301-0082(02)00009-6Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732–747.
doi:10.1017/S1092852900019726Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657–665.
doi:10.1124/jpet.106.103382Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338–347.
doi:10.1016/j.neuropharm.2013.02.024Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.
doi:10.1192/bjp.178.3.234Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427–452.
doi:10.2165/00023210-200923050-00006Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267–285.
doi:10.1016/S0165-0327(98)00224-9Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159–166.
doi:10.4088/PCC.v06n0403Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry. 1991;52(11):450–456.
Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195–1202.
doi:10.1056/NEJM199710233371703Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62–67.
doi:10.4088/jcp.v65n0110Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021. Chapters 9–10.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871–880.
doi:10.1016/S0893-133X(01)00298-6